Details of the Drug

General Information of Drug (ID: DMNOKBV)

Drug Name
Phenytoin
Synonyms
Aleviatin; Antisacer; Auranile; Causoin; Citrullamon; Citrulliamon; Comital; Comitoina; Convul; Danten; Dantinal; Dantoinal; Dantoine; Denyl; Difenilhidantoina; Difenin; Difetoin; Difhydan; Dihycon; Dihydantoin; Dilabid; Dilantin; Dilantine; Dillantin; Dintoin; Dintoina; Diphantoin; Diphedal; Diphedan; Diphenat; Diphenin; Diphenine; Diphentoin; Diphentyn; Diphenylan; Diphenylhydantoin; Diphenylhydantoine; Diphenylhydatanoin; Ditoinate; Ekko; Elepsindon; Enkelfel; Epamin; Epanutin; Epelin; Epifenyl; Epihydan; Epilantin; Epinat; Epised; Eptal; Eptoin; Fenitoin; Fenitoina; Fentoin; Fenylepsin; Fenytoine; Hidan; Hidantal; Hidantilo; Hidantina; Hidantomin; Hindatal; Hydantal; Hydantin; Hydantoinal; Hydantol; Idantoil; Idantoin; Iphenylhydantoin; Kessodanten; Labopal; Lehydan; Lepitoin; Lepsin; Minetoin; Neosidantoina; Novantoina; Novophenytoin; Oxylan; PHENYTEK; Phanantin; Phanatine; Phenatine; Phenatoine; Phenhydan; Phenhydanin; Phenitoin; Phentoin; Phentytoin; Phenytex; Phenytoine; Phenytoinum; Ritmenal; Saceril; Sanepil; Silantin; Sinergina; Sodanthon; Sodantoin; Sodanton; Solantin; Solantoin; Solantyl; Sylantoic;TOIN; Tacosal; Thilophenyl; Zentronal; Zentropil; Component of Mebroin; Dantoinal klinos; Difenilhidantoina [Spanish]; Dihydan toin; Dilantin acid; Diphenylhydantoine [French]; Ekko capsules; Elepsi ndon; Epdantoin Simple; Epdantoine simple; Epilan D; Extended Phenytoin Sodium; Fen toin; Fenantoin Mn Pharma; Fenidantoin s; Fenytoin Dak; Hidantina senosian; Hidantina vitoria; Ictalis simp le; Ictalis simple; Om hidantoina simple; Phenat ine; Phenytoin AWD; Sodium Diphenylhydantoinate; Taco sal; Toin unicelles; CL12003; D 4007; D4007_SIGMA; Didan TDC 250; Epasmir 5; IFLab1_000214; DILANTIN-30; DPH (VAN); Di-Hydan; Di-Lan; Di-Phetine; Dilantin (TN); Dilantin Infatabs (TN); Dilantin Kapseals (TN); Dilantin-125; Diphenylhydantoin (VAN); Epanutin (TN); Epasmir (5); Epilan-D; Eptoin (TN); Fenidantoin (s); Fenitoina [INN-Spanish]; Neos-Hidantoina; Om-Hydantoine; PHENYTOIN SODIUM, EXTENDED; Phenytek (TN); Phenytoin (PHN); Phenytoin-Gerot; Phenytoine [INN-French]; Phenytoinum [INN-Latin]; Di-Lan (VAN); Didan-tdc-250; Gerot-epilan-D; PHENYTOIN (5,5-DIPHENYLHYDANTOIN); Phenytoin (JP15/USP/INN); Phenytoin [USAN:INN:BAN:JAN]; Hydantoin, 5,5-diphenyl-(8CI); 2,4-Imidazolidinedione, 5,5-diphenyl-(9CI); 2-hydroxy-5,5-diphenyl-3,5-dihydro-4H-imidazol-4-one; 5,5-DIPHENYLHYDANTOIN; 5,5-Diphenyl-2,4-imidazolidinedione; 5,5-Diphenyl-imidazolidine-2,4-dione; 5,5-Diphenylhydantoin (IUPAC); 5,5-Diphenylhydantoin (phenytoin); 5,5-Diphenylimidazolidin-2,4-dione; 5,5-Dwufenylohydantoina; 5,5-Dwufenylohydantoina [Polish]; 5,5-diphenylimidazolidine-2,4-dione
Indication
Disease Entry ICD 11 Status REF
Epilepsy 8A60-8A68 Approved [1]
Epilepsy with generalized tonic-clonic seizures N.A. Approved [2]
Focal epilepsy N.A. Approved [2]
Primary motor cortex epilepsy N.A. Approved [2]
Therapeutic Class
Anticonvulsants
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 252.27
Logarithm of the Partition Coefficient (xlogp) 2.5
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1.5-3 h [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Bioavailability
90% of drug becomes completely available to its intended biological destination(s) [5]
Clearance
The drug present in the plasma can be removed from the body at the rate of 0.37 mL/min/kg [6]
Elimination
The majority of phenytoin is excreted as inactive metabolites in the bile, only estimated 1-5% of phenytoin is eliminated unchanged in the urine [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 7 - 42 hours [7]
Metabolism
The drug is metabolized via the CYP2C9 and CYP2C19 [8]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 19.81963 micromolar/kg/day [9]
Unbound Fraction
The unbound fraction of drug in plasma is 0.13% [6]
Vd
The volume of distribution (Vd) of drug is 0.75 L/kg [10]
Water Solubility
The ability of drug to dissolve in water is measured as 0.02 mg/mL [4]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Cleft palate Not Available NPR1 OTRWART5 [11]
Hypersensitivity rs9919839 DACH1 OTMKNAGG [12]
Hypersensitivity rs8083432 ZNF521 OTX468HL [12]
Hypersensitivity rs7798500 PRKAR2B OTZEXEFH [12]
Hypersensitivity rs4569005 NELL1 OTF3TX3N [12]
Hypersensitivity rs285406 ATP6V0D2 OTMOZJO0 [12]
Hypersensitivity rs275380 ADAMTS20 OTU0EKLN [12]
Hypersensitivity rs183266 IRF2BPL OTV8MNT1 [12]
Hypersensitivity rs12230440 ADIPOR2 OT2HDTL8 [12]
Hypersensitivity rs10510829 FHIT OTGWBSLA [12]
Jaundice Not Available ALPL OTG7J4BP [11]
Jaundice Not Available GPT OTOXOA0Q [11]
Jaundice Not Available GGT7 OTW4IO3I [11]
Poisoning and toxicity Not Available CYP2D6 OTZJC802 [11]
Thrombocytopenia Not Available EPHX2 OTPTRCNW [11]
Toxic epidermal necrolysis HLA-C*14:02 HLA-C OTV38BUJ [13]
Toxic epidermal necrolysis HLA-A*33:03 HLA-A OTAH14LU [13]
⏷ Show the Full List of 17 ADR Information of This Drug
Chemical Identifiers
Formula
C15H12N2O2
IUPAC Name
5,5-diphenylimidazolidine-2,4-dione
Canonical SMILES
C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3
InChI
InChI=1S/C15H12N2O2/c18-13-15(17-14(19)16-13,11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10H,(H2,16,17,18,19)
InChIKey
CXOFVDLJLONNDW-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
1775
ChEBI ID
CHEBI:8107
CAS Number
57-41-0
DrugBank ID
DB00252
TTD ID
D0E4DW
VARIDT ID
DR00431
INTEDE ID
DR1282
ACDINA ID
D00529
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Sodium channel unspecific (NaC) TTRK8B9 NOUNIPROTAC Blocker [14]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [15]
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [16]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [17]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [18]
Cytochrome P450 2C9 (CYP2C9)
Main DME 		DE5IED8 CP2C9_HUMAN Substrate [19]
Glutathione S-transferase alpha-1 (GSTA1) DE4ZHS1 GSTA1_HUMAN Substrate [20]
Mephenytoin 4-hydroxylase (CYP2C19)
Main DME 		DEGTFWK CP2CJ_HUMAN Substrate [21]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [22]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Substrate [22]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [21]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [22]
Cytochrome P450 2C18 (CYP2C18) DEZMWRE CP2CI_HUMAN Substrate [21]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
72 kDa type IV collagenase (MMP2) OT5NIWA2 MMP2_HUMAN Gene/Protein Processing [23]
A disintegrin and metalloproteinase with thrombospondin motifs 20 (ADAMTS20) OTU0EKLN ATS20_HUMAN Drug Response [12]
Adiponectin receptor protein 2 (ADIPOR2) OT2HDTL8 PAQR2_HUMAN Drug Response [12]
Alanine aminotransferase 1 (GPT) OTOXOA0Q ALAT1_HUMAN Drug Response [11]
Alkaline phosphatase, tissue-nonspecific isozyme (ALPL) OTG7J4BP PPBT_HUMAN Drug Response [11]
Alpha-fetoprotein (AFP) OT9GG3ZI FETA_HUMAN Gene/Protein Processing [24]
Angiotensin-converting enzyme 2 (ACE2) OTTRZGU7 ACE2_HUMAN Gene/Protein Processing [25]
Annexin A4 (ANXA4) OTUCRYXL ANXA4_HUMAN Gene/Protein Processing [24]
Aromatase (CYP19A1) OTZ6XF74 CP19A_HUMAN Gene/Protein Processing [26]
ATP-binding cassette sub-family C member 2 (ABCC2) OTJSIGV5 MRP2_HUMAN Drug Response [27]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Phenytoin
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Diazepam DM08E9O Moderate Increased metabolism of Phenytoin caused by Diazepam mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [28]
Zonisamide DM0DTF7 Moderate Increased metabolism of Phenytoin caused by Zonisamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [29]
Primidone DM0WX6I Moderate Increased metabolism of Phenytoin caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [30]
Oxcarbazepine DM5PU6O Moderate Decreased metabolism of Phenytoin caused by Oxcarbazepine mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [31]
Methsuximide DM6L5VO Moderate Increased metabolism of Phenytoin caused by Methsuximide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [32]
Valproate DMCFE9I Moderate Increased plasma concentration of Phenytoin and Valproate due to competitive binding of plasma proteins. Epilepsy/seizure [8A61-8A6Z] [33]
Ethosuximide DMDZ9LT Moderate Increased metabolism of Phenytoin caused by Ethosuximide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [32]
Cenobamate DM8KLU9 Major Increased metabolism of Phenytoin caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [34]
Tiagabine DMKSQG0 Moderate Increased metabolism of Phenytoin caused by Tiagabine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [35]
Stiripentol DMMSDOY Major Increased metabolism of Phenytoin caused by Stiripentol mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [36]
Brivaracetam DMSEPK8 Moderate Increased metabolism of Phenytoin caused by Brivaracetam mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [37]
Clonazepam DMTO13J Moderate Increased metabolism of Phenytoin caused by Clonazepam mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [28]
Lacosamide DMVM6QR Minor Increased metabolism of Phenytoin caused by Lacosamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [37]
Phenobarbital DMXZOCG Moderate Increased metabolism of Phenytoin caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [30]
Carbamazepine DMZOLBI Moderate Increased metabolism of Phenytoin caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [38]
Eslicarbazepine DMZREFQ Moderate Decreased metabolism of Phenytoin caused by Eslicarbazepine mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [39]
⏷ Show the Full List of 16 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Phenytoin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Accelerated clearance of Phenytoin due to the transporter induction by Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [37]
Methylergonovine DMBEX4O Moderate Increased metabolism of Phenytoin caused by Methylergonovine mediated induction of CYP450 enzyme. Abortion [JA00] [40]
Clindamycin DM15HL8 Moderate Increased metabolism of Phenytoin caused by Clindamycin mediated induction of CYP450 enzyme. Acne vulgaris [ED80] [41]
Sucralfate DMP9HBO Moderate Decreased absorption of Phenytoin due to formation of complexes caused by Sucralfate. Acne vulgaris [ED80] [42]
Repaglinide DM5SXUV Moderate Increased metabolism of Phenytoin caused by Repaglinide mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [43]
Thioguanine DM7NKEV Moderate Increased risk of hepatotoxicity by the combination of Phenytoin and Thioguanine. Acute myeloid leukaemia [2A60] [44]
Ivosidenib DM8S6T7 Major Increased metabolism of Phenytoin caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [45]
Midostaurin DMI6E0R Major Increased metabolism of Phenytoin caused by Midostaurin mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [46]
Gilteritinib DMTI0ZO Major Accelerated clearance of Phenytoin due to the transporter induction by Gilteritinib. Acute myeloid leukaemia [2A60] [47]
Oliceridine DM6MDCF Major Increased metabolism of Phenytoin caused by Oliceridine mediated induction of CYP450 enzyme. Acute pain [MG31] [40]
Emapalumab DMZG5WL Moderate Altered metabolism of Phenytoin due to Emapalumab alters the formation of CYP450 enzymes. Adaptive immunity immunodeficiency [4A01] [37]
Mitotane DMU1GX0 Minor Increased metabolism of Phenytoin caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [48]
Donepezil DMIYG7Z Moderate Increased metabolism of Phenytoin caused by Donepezil mediated induction of CYP450 enzyme. Alzheimer disease [8A20] [49]
Metronidazole DMTIVEN Moderate Decreased metabolism of Phenytoin caused by Metronidazole mediated inhibition of CYP450 enzyme. Amoebiasis [1A36] [50]
Siltuximab DMGEATB Moderate Altered metabolism of Phenytoin due to Siltuximab alters the formation of CYP450 enzymes. Anemia [3A00-3A9Z] [37]
Ivabradine DM0L594 Major Increased metabolism of Phenytoin caused by Ivabradine mediated induction of CYP450 enzyme. Angina pectoris [BA40] [37]
Bepridil DM0RKS4 Major Increased metabolism of Phenytoin caused by Bepridil mediated induction of CYP450 enzyme. Angina pectoris [BA40] [51]
Dronedarone DMA8FS5 Moderate Increased metabolism of Phenytoin caused by Dronedarone mediated induction of CYP450 enzyme. Angina pectoris [BA40] [52]
Nifedipine DMSVOZT Major Increased metabolism of Phenytoin caused by Nifedipine mediated induction of CYP450 enzyme. Angina pectoris [BA40] [51]
Bedaquiline DM3906J Major Increased metabolism of Phenytoin caused by Bedaquiline mediated induction of CYP450 enzyme. Antimicrobial drug resistance [MG50-MG52] [37]
Buspirone DMBS632 Major Increased metabolism of Phenytoin caused by Buspirone mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [53]
Clorazepate DMC3JST Moderate Increased metabolism of Phenytoin caused by Clorazepate mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [54]
Alprazolam DMC7XDN Moderate Increased metabolism of Phenytoin caused by Alprazolam mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [28]
Methylphenobarbital DMDSWAG Moderate Increased metabolism of Phenytoin caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [30]
Halazepam DMPFWO6 Moderate Increased metabolism of Phenytoin caused by Halazepam mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [28]
Chlordiazepoxide DMTN5XI Moderate Increased metabolism of Phenytoin caused by Chlordiazepoxide mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [28]
Clobazam - Lundbeck DMW1OQ0 Moderate Increased metabolism of Phenytoin caused by Clobazam - Lundbeck mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [28]
Oxazepam DMXNZM4 Moderate Increased metabolism of Phenytoin caused by Oxazepam mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [28]
Voriconazole DMAOL2S Major Increased metabolism of Phenytoin caused by Voriconazole mediated induction of CYP450 enzyme. Aspergillosis [1F20] [55]
Posaconazole DMUL5EW Moderate Increased metabolism of Phenytoin caused by Posaconazole mediated induction of UGT. Aspergillosis [1F20] [37]
Montelukast DMD157S Moderate Increased metabolism of Phenytoin caused by Montelukast mediated induction of CYP450 enzyme. Asthma [CA23] [56]
Aminophylline DML2NIB Moderate Increased metabolism of Phenytoin caused by Aminophylline mediated induction of CYP450 enzyme. Asthma [CA23] [57]
Roflumilast DMPGHY8 Moderate Increased metabolism of Phenytoin caused by Roflumilast mediated induction of CYP450 enzyme. Asthma [CA23] [58]
Methylphenidate DM7SJD6 Minor Decreased metabolism of Phenytoin caused by Methylphenidate mediated inhibition of CYP450 enzyme. Attention deficit hyperactivity disorder [6A05] [59]
Desipramine DMT2FDC Moderate Decreased metabolism of Phenytoin caused by Desipramine mediated inhibition of CYP450 enzyme. Attention deficit hyperactivity disorder [6A05] [60]
Tindamax DM3OWT4 Moderate Decreased metabolism of Phenytoin caused by Tindamax mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [50]
Clarithromycin DM4M1SG Moderate Increased metabolism of Phenytoin caused by Clarithromycin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [61]
Sulfamethoxazole DMB08GE Minor Increased plasma concentration of Phenytoin and Sulfamethoxazole due to competitive binding of plasma proteins. Bacterial infection [1A00-1C4Z] [62]
Ceftriaxone DMCEW64 Minor Increased plasma concentration of Phenytoin and Ceftriaxone due to competitive binding of plasma proteins. Bacterial infection [1A00-1C4Z] [62]
Troleandomycin DMUZNIG Moderate Increased metabolism of Phenytoin caused by Troleandomycin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [61]
Telithromycin DMZ4P3A Major Increased metabolism of Phenytoin caused by Telithromycin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [37]
Retigabine DMGNYIH Moderate Increased metabolism of Phenytoin caused by Retigabine mediated induction of UGT. Behcet disease [4A62] [63]
Lamotrigine DM8SXYG Moderate Increased metabolism of Phenytoin caused by Lamotrigine mediated induction of UGT. Bipolar disorder [6A60] [64]
Cariprazine DMJYDVK Moderate Increased metabolism of Phenytoin caused by Cariprazine mediated induction of CYP450 enzyme. Bipolar disorder [6A60] [65]
Erdafitinib DMI782S Major Increased metabolism of Phenytoin caused by Erdafitinib mediated induction of CYP450 enzyme. Bladder cancer [2C94] [66]
Pexidartinib DMS2J0Z Major Decreased metabolism of Phenytoin caused by Pexidartinib mediated inhibition of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [67]
Nitazoxanide DMOWLVG Moderate Increased plasma concentration of Phenytoin and Nitazoxanide due to competitive binding of plasma proteins. Bowel habit change [ME05] [68]
Ixabepilone DM2OZ3G Moderate Increased metabolism of Phenytoin caused by Ixabepilone mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [69]
Lapatinib DM3BH1Y Moderate Increased metabolism of Phenytoin caused by Lapatinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [40]
HKI-272 DM6QOVN Major Increased metabolism of Phenytoin caused by HKI-272 mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [40]
LY2835219 DM93VBZ Major Increased metabolism of Phenytoin caused by LY2835219 mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [70]
Exemestane DM9HPW3 Moderate Increased metabolism of Phenytoin caused by Exemestane mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [71]
Esterified estrogens DM9KZDO Moderate Increased metabolism of Phenytoin caused by Esterified estrogens mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [72]
Tucatinib DMBESUA Major Increased metabolism of Phenytoin caused by Tucatinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [73]
Alpelisib DMEXMYK Major Increased metabolism of Phenytoin caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [74]
Thiotepa DMIZKOP Moderate Increased metabolism of Phenytoin caused by Thiotepa mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [75]
Quinestrol DMJ6H1Z Moderate Increased metabolism of Phenytoin caused by Quinestrol mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [72]
Tamoxifen DMLB0EZ Moderate Increased metabolism of Phenytoin caused by Tamoxifen mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [76]
Cabazitaxel DMPAZHC Moderate Increased metabolism of Phenytoin caused by Cabazitaxel mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [77]
Toremifene DMQYUWG Major Increased metabolism of Phenytoin caused by Toremifene mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [78]
Bosutinib DMTI8YE Major Increased metabolism of Phenytoin caused by Bosutinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [79]
Estradiol DMUNTE3 Moderate Increased metabolism of Phenytoin caused by Estradiol mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [80]
Atorvastatin DMF28YC Moderate Increased metabolism of Phenytoin caused by Atorvastatin mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [81]
Macitentan DMP79A1 Major Increased metabolism of Phenytoin caused by Macitentan mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [82]
Secobarbital DM14RF5 Moderate Increased metabolism of Phenytoin caused by Secobarbital mediated induction of CYP450 enzyme. Chronic insomnia [7A00] [30]
Doxercalciferol DM6FG1P Moderate Increased metabolism of Phenytoin caused by Doxercalciferol mediated induction of CYP450 enzyme. Chronic kidney disease [GB61] [83]
PF-04449913 DMSB068 Major Increased metabolism of Phenytoin caused by PF-04449913 mediated induction of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [84]
Dihydrocodeine DMB0FWL Moderate Increased metabolism of Phenytoin caused by Dihydrocodeine mediated induction of CYP450 enzyme. Chronic pain [MG30] [85]
Anisindione DM2C48U Moderate Increased metabolism of Phenytoin caused by Anisindione mediated induction of CYP450 enzyme. Coagulation defect [3B10] [86]
Regorafenib DMHSY1I Moderate Increased metabolism of Phenytoin caused by Regorafenib mediated induction of CYP450 enzyme. Colorectal cancer [2B91] [87]
Irinotecan DMP6SC2 Major Increased metabolism of Phenytoin caused by Irinotecan mediated induction of CYP450 enzyme. Colorectal cancer [2B91] [88]
Intedanib DMSTA36 Major Accelerated clearance of Phenytoin due to the transporter induction by Intedanib. Colorectal cancer [2B91] [89]
Drospirenone DM1A9W3 Major Increased metabolism of Phenytoin caused by Drospirenone mediated induction of CYP450 enzyme. Contraceptive management [QA21] [72]
Levonorgestrel DM1DP7T Major Increased metabolism of Phenytoin caused by Levonorgestrel mediated induction of CYP450 enzyme. Contraceptive management [QA21] [72]
Ulipristal DMBNI20 Moderate Increased metabolism of Phenytoin caused by Ulipristal mediated induction of CYP450 enzyme. Contraceptive management [QA21] [37]
Etonogestrel DMKA8J4 Major Increased metabolism of Phenytoin caused by Etonogestrel mediated induction of CYP450 enzyme. Contraceptive management [QA21] [72]
Norgestimate DMYP4XC Major Increased metabolism of Phenytoin caused by Norgestimate mediated induction of CYP450 enzyme. Contraceptive management [QA21] [90]
Atracurium DM42HXN Moderate Increased metabolism of Phenytoin caused by Atracurium mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [91]
Mivacurium DM473VD Moderate Increased metabolism of Phenytoin caused by Mivacurium mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [91]
Bupivacaine DM4PRFC Minor Increased plasma concentration of Phenytoin and Bupivacaine due to competitive binding of plasma proteins. Corneal disease [9A76-9A78] [37]
Methohexital DM7YMIT Moderate Increased metabolism of Phenytoin caused by Methohexital mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [30]
Pancuronium DMB0VY8 Moderate Increased metabolism of Phenytoin caused by Pancuronium mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [91]
Alfentanil DMVO0UB Moderate Increased metabolism of Phenytoin caused by Alfentanil mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [92]
Nimodipine DMQ0RKZ Major Increased metabolism of Phenytoin caused by Nimodipine mediated induction of CYP450 enzyme. Coronary vasospastic disease [BA85] [93]
Oxtriphylline DMLHSE3 Moderate Increased metabolism of Phenytoin caused by Oxtriphylline mediated induction of CYP450 enzyme. Cough [MD12] [57]
Methadone DMTW6IU Major Increased metabolism of Phenytoin caused by Methadone mediated induction of CYP450 enzyme. Cough [MD12] [94]
Mycophenolic acid DMRBMAU Minor Increased plasma concentration of Phenytoin and Mycophenolic acid due to competitive binding of plasma proteins. Crohn disease [DD70] [95]
Mifepristone DMGZQEF Moderate Increased metabolism of Phenytoin caused by Mifepristone mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [96]
Osilodrostat DMIJC9X Major Increased metabolism of Phenytoin caused by Osilodrostat mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [37]
Ivacaftor DMZC1HS Major Increased metabolism of Phenytoin caused by Ivacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [40]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Phenytoin and Ethanol. Cystitis [GC00] [40]
MK-8228 DMOB58Q Moderate Accelerated clearance of Phenytoin due to the transporter induction by MK-8228. Cytomegaloviral disease [1D82] [40]
Rivaroxaban DMQMBZ1 Major Increased metabolism of Phenytoin caused by Rivaroxaban mediated induction of CYP450 enzyme. Deep vein thrombosis [BD71] [97]
Aprepitant DM053KT Moderate Increased metabolism of Phenytoin caused by Aprepitant mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [98]
Sertraline DM0FB1J Moderate Decreased metabolism of Phenytoin caused by Sertraline mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [40]
Trimipramine DM1SC8M Moderate Decreased metabolism of Phenytoin caused by Trimipramine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [60]
Imipramine DM2NUH3 Moderate Decreased metabolism of Phenytoin caused by Imipramine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [60]
Fluoxetine DM3PD2C Moderate Decreased metabolism of Phenytoin caused by Fluoxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [99]
Vilazodone DM4LECQ Moderate Increased metabolism of Phenytoin caused by Vilazodone mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [100]
Paroxetine DM5PVQE Moderate Antagonize the effect of Phenytoin when combined with Paroxetine. Depression [6A70-6A7Z] [101]
Vortioxetine DM6F1PU Moderate Increased metabolism of Phenytoin caused by Vortioxetine mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [102]
OPC-34712 DMHG57U Moderate Increased metabolism of Phenytoin caused by OPC-34712 mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [103]
Clomipramine DMINRKW Moderate Decreased metabolism of Phenytoin caused by Clomipramine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [60]
Amitriptyline DMK7F9S Moderate Decreased metabolism of Phenytoin caused by Amitriptyline mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [60]
Amoxapine DMKITQE Moderate Decreased metabolism of Phenytoin caused by Amoxapine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [60]
Mirtazapine DML53ZJ Moderate Increased metabolism of Phenytoin caused by Mirtazapine mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [104]
Protriptyline DMNHTZI Moderate Decreased metabolism of Phenytoin caused by Protriptyline mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [60]
Doxepin DMPI98T Moderate Decreased metabolism of Phenytoin caused by Doxepin mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [60]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Phenytoin and Esketamine. Depression [6A70-6A7Z] [40]
Empagliflozin DMRF9YK Moderate Increased metabolism of Phenytoin caused by Empagliflozin mediated induction of UGT. Diabetes mellitus [5A10] [40]
Polatuzumab vedotin DMF6Y0L Minor Increased metabolism of Phenytoin caused by Polatuzumab vedotin mediated induction of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [40]
[3H]estrone-3-sulphate DMGPF0N Moderate Increased metabolism of Phenytoin caused by [3H]estrone-3-sulphate mediated induction of CYP450 enzyme. Discovery agent [N.A.] [80]
PMID28870136-Compound-48 DMPIM9L Moderate Increased metabolism of Phenytoin caused by PMID28870136-Compound-48 mediated induction of CYP450 enzyme. Discovery agent [N.A.] [57]
Ospemifene DMC4GEI Moderate Increased metabolism of Phenytoin caused by Ospemifene mediated induction of CYP450 enzyme. Dyspareunia [GA12] [105]
Ingrezza DMVPLNC Major Increased metabolism of Phenytoin caused by Ingrezza mediated induction of CYP450 enzyme. Dystonic disorder [8A02] [106]
Oestradiol valerate and dienogest DMZK0FQ Major Increased metabolism of Phenytoin caused by Oestradiol valerate and dienogest mediated induction of CYP450 enzyme. Endometriosis [GA10] [90]
Cannabidiol DM0659E Moderate Increased metabolism of Phenytoin caused by Cannabidiol mediated induction of CYP450 enzyme. Epileptic encephalopathy [8A62] [37]
Nicardipine DMCDYW7 Major Increased metabolism of Phenytoin caused by Nicardipine mediated induction of CYP450 enzyme. Essential hypertension [BA00] [51]
Praziquantel DMOU1PK Major Increased metabolism of Phenytoin caused by Praziquantel mediated induction of CYP450 enzyme. Flatworm infection [1F70-1F86] [107]
Bay 80-6946 DMLOS5R Major Accelerated clearance of Phenytoin due to the transporter induction by Bay 80-6946. Follicular lymphoma [2A80] [108]
Tazemetostat DMWP1BH Major Increased metabolism of Phenytoin caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [109]
Solifenacin DMG592Q Moderate Increased metabolism of Phenytoin caused by Solifenacin mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [110]
Mirabegron DMS1GYT Minor Increased metabolism of Phenytoin caused by Mirabegron mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [111]
Darifenacin DMWXLYZ Moderate Increased metabolism of Phenytoin caused by Darifenacin mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [112]
Itraconazole DMCR1MV Moderate Increased metabolism of Phenytoin caused by Itraconazole mediated induction of CYP450 enzyme. Fungal infection [1F29-1F2F] [40]
Caspofungin DMGQIPT Major Increased metabolism of Phenytoin caused by Caspofungin mediated induction of CYP450 enzyme. Fungal infection [1F29-1F2F] [113]
Miconazole DMPMYE8 Moderate Decreased metabolism of Phenytoin caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [114]
Ketoconazole DMPZI3Q Moderate Increased metabolism of Phenytoin caused by Ketoconazole mediated induction of CYP450 enzyme. Fungal infection [1F29-1F2F] [40]
Omeprazole DM471KJ Moderate Decreased metabolism of Phenytoin caused by Omeprazole mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [115]
Cimetidine DMH61ZB Major Decreased metabolism of Phenytoin caused by Cimetidine mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [116]
Ripretinib DM958QB Major Increased metabolism of Phenytoin caused by Ripretinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [117]
Sunitinib DMCBJSR Major Increased metabolism of Phenytoin caused by Sunitinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [40]
Avapritinib DMK2GZX Major Increased metabolism of Phenytoin caused by Avapritinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [37]
Brimonidine DMQLT4N Moderate Additive CNS depression effects by the combination of Phenytoin and Brimonidine. Glaucoma [9C61] [118]
Sulfinpyrazone DMEV954 Moderate Increased plasma concentration of Phenytoin and Sulfinpyrazone due to competitive binding of plasma proteins. Gout [FA25] [37]
Ergotamine DMKR3C5 Moderate Increased metabolism of Phenytoin caused by Ergotamine mediated induction of CYP450 enzyme. Headache [8A80-8A84] [40]
Eplerenone DMF0NQR Minor Increased metabolism of Phenytoin caused by Eplerenone mediated induction of CYP450 enzyme. Heart failure [BD10-BD1Z] [60]
Boceprevir DMBSHMF Major Increased metabolism of Phenytoin caused by Boceprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [119]
PSI-7977 DMLSUWZ Major Accelerated clearance of Phenytoin due to the transporter induction by PSI-7977. Hepatitis virus infection [1E50-1E51] [37]
Simeprevir DMLUA9D Major Increased metabolism of Phenytoin caused by Simeprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [120]
Telaprevir DMMRV29 Major Increased metabolism of Phenytoin caused by Telaprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [121]
ABT-267 DMNQ869 Major Increased metabolism of Phenytoin caused by ABT-267 mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [37]
Daclatasvir DMSFK9V Major Increased metabolism of Phenytoin caused by Daclatasvir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [37]
Isoniazid DM5JVS3 Moderate Decreased metabolism of Phenytoin caused by Isoniazid mediated inhibition of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [40]
Rifampin DMA8J1G Major Increased metabolism of Phenytoin caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [122]
Rifapentine DMCHV4I Moderate Increased metabolism of Phenytoin caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [123]
Pretomanid DMDYA31 Major Increased metabolism of Phenytoin caused by Pretomanid mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [124]
MK-1439 DM215WE Major Increased metabolism of Phenytoin caused by MK-1439 mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [125]
Delavirdine DM3NF5G Major Increased metabolism of Phenytoin caused by Delavirdine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [126]
Fosamprenavir DM4W9B3 Moderate Increased metabolism of Phenytoin caused by Fosamprenavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [127]
Cobicistat DM6L4H2 Major Increased metabolism of Phenytoin caused by Cobicistat mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [40]
Tipranavir DM8HJX6 Moderate Decreased metabolism of Phenytoin caused by Tipranavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [128]
Efavirenz DMC0GSJ Moderate Increased metabolism of Phenytoin caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [129]
Dolutegravir DMCZGRE Major Increased metabolism of Phenytoin caused by Dolutegravir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [40]
Saquinavir DMG814N Moderate Increased metabolism of Phenytoin caused by Saquinavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [128]
Elvitegravir DMG9B1U Major Increased metabolism of Phenytoin caused by Elvitegravir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [40]
Etravirine DMGV8QU Major Increased metabolism of Phenytoin caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [130]
Lopinavir DMITQS0 Major Increased metabolism of Phenytoin caused by Lopinavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [40]
Rilpivirine DMJ0QOW Major Increased metabolism of Phenytoin caused by Rilpivirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [131]
Amprenavir DMLMXE0 Moderate Increased metabolism of Phenytoin caused by Amprenavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [127]
Darunavir DMN3GCH Major Increased metabolism of Phenytoin caused by Darunavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [97]
Atazanavir DMSYRBX Moderate Increased metabolism of Phenytoin caused by Atazanavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [128]
GSK1265744 DMT8J0I Major Increased metabolism of Phenytoin caused by GSK1265744 mediated induction of UGT. Human immunodeficiency virus disease [1C60-1C62] [132]
Ritonavir DMU764S Moderate Increased metabolism of Phenytoin caused by Ritonavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [127]
Raltegravir DMYURI6 Minor Increased metabolism of Phenytoin caused by Raltegravir mediated induction of UGT. Human immunodeficiency virus disease [1C60-1C62] [97]
Fenofibrate DMFKXDY Moderate Decreased metabolism of Phenytoin caused by Fenofibrate mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [40]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Phenytoin and Mipomersen. Hyper-lipoproteinaemia [5C80] [133]
Clofibrate DMPC1J7 Minor Increased plasma concentration of Phenytoin and Clofibrate due to competitive binding of plasma proteins. Hyper-lipoproteinaemia [5C80] [134]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Phenytoin and BMS-201038. Hyper-lipoproteinaemia [5C80] [135]
Paricalcitol DMYBV3G Moderate Increased metabolism of Phenytoin caused by Paricalcitol mediated induction of CYP450 enzyme. Hyper-parathyroidism [5A51] [83]
Losartan DM72JXH Moderate Increased metabolism of Phenytoin caused by Losartan mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [136]
Nisoldipine DM7ISKJ Major Increased metabolism of Phenytoin caused by Nisoldipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [51]
Levamlodipine DM92S6N Major Increased metabolism of Phenytoin caused by Levamlodipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [51]
Isradipine DMA5XGH Major Increased metabolism of Phenytoin caused by Isradipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [51]
Diltiazem DMAI7ZV Moderate Increased metabolism of Phenytoin caused by Diltiazem mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [137]
Amlodipine DMBDAZV Major Increased metabolism of Phenytoin caused by Amlodipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [51]
Diazoxide DML1538 Moderate Increased metabolism of Phenytoin caused by Diazoxide mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [138]
Felodipine DMOSW35 Major Increased metabolism of Phenytoin caused by Felodipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [51]
Quinapril DMR8H31 Moderate Decreased absorption of Phenytoin due to formation of complexes caused by Quinapril. Hypertension [BA00-BA04] [37]
Tolvaptan DMIWFRL Major Increased metabolism of Phenytoin caused by Tolvaptan mediated induction of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [37]
Fludrocortisone DMUDIR8 Moderate Increased metabolism of Phenytoin caused by Fludrocortisone mediated induction of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [139]
Liothyronine DM6IR3P Moderate Increased plasma concentration of Phenytoin and Liothyronine due to competitive binding of plasma proteins. Hypo-thyroidism [5A00] [37]
Levothyroxine DMHN027 Moderate Increased metabolism of Phenytoin caused by Levothyroxine mediated induction of CYP450 enzyme. Hypo-thyroidism [5A00] [37]
Pirfenidone DM6VZFQ Moderate Increased metabolism of Phenytoin caused by Pirfenidone mediated induction of CYP450 enzyme. Idiopathic interstitial pneumonitis [CB03] [37]
Febuxostat DMDEXQ0 Minor Increased metabolism of Phenytoin caused by Febuxostat mediated induction of UGT. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [37]
Lesinurad DMUR64T Moderate Increased metabolism of Phenytoin caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [140]
TP-434 DM5A31S Major Increased metabolism of Phenytoin caused by TP-434 mediated induction of CYP450 enzyme. Infectious gastroenteritis/colitis [1A40] [141]
Suvorexant DM0E6S3 Major Increased metabolism of Phenytoin caused by Suvorexant mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [142]
Amobarbital DM0GQ8N Moderate Increased metabolism of Phenytoin caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [30]
Ramelteon DM7IW9J Moderate Increased metabolism of Phenytoin caused by Ramelteon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [143]
Eszopiclone DM8RZ9H Moderate Increased metabolism of Phenytoin caused by Eszopiclone mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [144]
Flurazepam DMAL4G0 Moderate Increased metabolism of Phenytoin caused by Flurazepam mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [28]
Triazolam DMETYK5 Moderate Increased metabolism of Phenytoin caused by Triazolam mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [28]
Pentobarbital DMFNH7L Moderate Increased metabolism of Phenytoin caused by Pentobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [30]
Zaleplon DMGFWSM Moderate Increased metabolism of Phenytoin caused by Zaleplon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [145]
Tasimelteon DMLOQ1V Major Increased metabolism of Phenytoin caused by Tasimelteon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [146]
Zolpidem DMWOSKJ Moderate Increased metabolism of Phenytoin caused by Zolpidem mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [37]
Quazepam DMY4D87 Moderate Increased metabolism of Phenytoin caused by Quazepam mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [28]
Estazolam DMZGXUM Moderate Increased metabolism of Phenytoin caused by Estazolam mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [28]
Remimazolam DMLVSYX Moderate Increased metabolism of Phenytoin caused by Remimazolam mediated induction of CYP450 enzyme. Labour/delivery anaesthesia complication [JB0C] [28]
Naloxegol DML0B41 Major Increased metabolism of Phenytoin caused by Naloxegol mediated induction of CYP450 enzyme. Large intestine motility disorder [DB32] [37]
Methotrexate DM2TEOL Moderate Increased risk of hepatotoxicity by the combination of Phenytoin and Methotrexate. Leukaemia [2A60-2B33] [37]
Crizotinib DM4F29C Major Increased metabolism of Phenytoin caused by Crizotinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [40]
Brigatinib DM7W94S Major Increased metabolism of Phenytoin caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [147]
Ceritinib DMB920Z Major Increased metabolism of Phenytoin caused by Ceritinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [148]
Erlotinib DMCMBHA Moderate Increased metabolism of Phenytoin caused by Erlotinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [149]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Phenytoin caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [150]
PF-06463922 DMKM7EW Major Increased metabolism of Phenytoin caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [151]
Osimertinib DMRJLAT Major Increased metabolism of Phenytoin caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [40]
BIBW 2992 DMTKD7Q Moderate Accelerated clearance of Phenytoin due to the transporter induction by BIBW 2992. Lung cancer [2C25] [152]
Pralsetinib DMWU0I2 Major Increased metabolism of Phenytoin caused by Pralsetinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [153]
Capmatinib DMYCXKL Major Increased metabolism of Phenytoin caused by Capmatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [154]
Selpercatinib DMZR15V Major Increased metabolism of Phenytoin caused by Selpercatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [37]
Artemether DM48QOT Major Increased metabolism of Phenytoin caused by Artemether mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [40]
Artesunate DMR27C8 Moderate Increased metabolism of Phenytoin caused by Artesunate mediated induction of UGT. Malaria [1F40-1F45] [155]
Chloroquine DMSI5CB Moderate Increased metabolism of Phenytoin caused by Chloroquine mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [40]
Hydroxychloroquine DMSIVND Moderate Antagonize the effect of Phenytoin when combined with Hydroxychloroquine. Malaria [1F40-1F45] [40]
Quinine DMSWYF5 Moderate Increased metabolism of Phenytoin caused by Quinine mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [156]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Phenytoin and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [157]
Idelalisib DM602WT Major Accelerated clearance of Phenytoin due to the transporter induction by Idelalisib. Mature B-cell leukaemia [2A82] [158]
GDC-0199 DMH0QKA Major Increased metabolism of Phenytoin caused by GDC-0199 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [159]
IPI-145 DMWA24P Major Increased metabolism of Phenytoin caused by IPI-145 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [160]
Acalabrutinib DM7GCVW Major Increased metabolism of Phenytoin caused by Acalabrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [161]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Phenytoin and Clofarabine. Mature B-cell lymphoma [2A85] [162]
Blinatumomab DMGECIJ Moderate Decreased metabolism of Phenytoin caused by Blinatumomab mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [163]
Ibrutinib DMHZCPO Major Increased metabolism of Phenytoin caused by Ibrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [37]
Vincristine DMINOX3 Moderate Accelerated clearance of Phenytoin due to the transporter induction by Vincristine. Mature B-cell lymphoma [2A85] [164]
Teniposide DMLW57T Moderate Increased metabolism of Phenytoin caused by Teniposide mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [165]
Ponatinib DMYGJQO Moderate Increased metabolism of Phenytoin caused by Ponatinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [40]
Arry-162 DM1P6FR Moderate Increased metabolism of Phenytoin caused by Arry-162 mediated induction of UGT. Melanoma [2C30] [40]
Selumetinib DMC7W6R Major Increased metabolism of Phenytoin caused by Selumetinib mediated induction of CYP450 enzyme. Melanoma [2C30] [166]
LGX818 DMNQXV8 Major Increased metabolism of Phenytoin caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [167]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Phenytoin caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [40]
Estrone DM5T6US Moderate Increased metabolism of Phenytoin caused by Estrone mediated induction of CYP450 enzyme. Menopausal disorder [GA30] [72]
Conjugated estrogens DMLT0E1 Moderate Increased metabolism of Phenytoin caused by Conjugated estrogens mediated induction of CYP450 enzyme. Menopausal disorder [GA30] [72]
Ethinyl estradiol DMODJ40 Major Increased metabolism of Phenytoin caused by Ethinyl estradiol mediated induction of CYP450 enzyme. Menopausal disorder [GA30] [90]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Phenytoin and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [168]
Nitisinone DMVS9WQ Moderate Decreased metabolism of Phenytoin caused by Nitisinone mediated inhibition of CYP450 enzyme. Metabolism inborn error [5C50] [97]
Dihydroergotamine DM5IKUF Moderate Increased metabolism of Phenytoin caused by Dihydroergotamine mediated induction of CYP450 enzyme. Migraine [8A80] [40]
Rimegepant DMHOAUG Major Increased metabolism of Phenytoin caused by Rimegepant mediated induction of CYP450 enzyme. Migraine [8A80] [169]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Phenytoin and Lasmiditan. Migraine [8A80] [170]
Exjade DMHPRWG Moderate Increased metabolism of Phenytoin caused by Exjade mediated induction of UGT. Mineral absorption/transport disorder [5C64] [40]
Lanthanum carbonate DMMJQSH Moderate Decreased absorption of Phenytoin due to formation of complexes caused by Lanthanum carbonate. Mineral absorption/transport disorder [5C64] [97]
Dihydrotachysterol DMFB97P Moderate Increased metabolism of Phenytoin caused by Dihydrotachysterol mediated induction of CYP450 enzyme. Mineral deficiency [5B5K] [83]
Flibanserin DM70DTN Major Increased metabolism of Phenytoin caused by Flibanserin mediated induction of CYP450 enzyme. Mood disorder [6A60-6E23] [171]
Midazolam DMXOELT Moderate Increased metabolism of Phenytoin caused by Midazolam mediated induction of CYP450 enzyme. Mood/affect symptom [MB24] [28]
Panobinostat DM58WKG Major Increased metabolism of Phenytoin caused by Panobinostat mediated induction of CYP450 enzyme. Multiple myeloma [2A83] [172]
Thalidomide DM70BU5 Moderate Increased risk of peripheral neuropathy by the combination of Phenytoin and Thalidomide. Multiple myeloma [2A83] [173]
Siponimod DM2R86O Major Increased metabolism of Phenytoin caused by Siponimod mediated induction of CYP450 enzyme. Multiple sclerosis [8A40] [40]
Deflazacort DMV0RNS Major Increased metabolism of Phenytoin caused by Deflazacort mediated induction of CYP450 enzyme. Muscular dystrophy [8C70] [37]
Rifabutin DM1YBHK Moderate Increased metabolism of Phenytoin caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [122]
Romidepsin DMT5GNL Moderate Increased metabolism of Phenytoin caused by Romidepsin mediated induction of CYP450 enzyme. Mycosis fungoides [2B01] [174]
Fedratinib DM4ZBK6 Major Increased metabolism of Phenytoin caused by Fedratinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [37]
Nilotinib DM7HXWT Major Increased metabolism of Phenytoin caused by Nilotinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [175]
Imatinib DM7RJXL Major Decreased metabolism of Phenytoin caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [176]
Vorapaxar DMA16BR Major Increased metabolism of Phenytoin caused by Vorapaxar mediated induction of CYP450 enzyme. Myocardial infarction [BA41-BA43] [177]
Modafinil DMYILBE Moderate Increased metabolism of Phenytoin caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [40]
Rolapitant DM8XP26 Major Increased metabolism of Phenytoin caused by Rolapitant mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [37]
Netupitant DMEKAYI Major Increased metabolism of Phenytoin caused by Netupitant mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [40]
Ondansetron DMOTQ1I Moderate Increased metabolism of Phenytoin caused by Ondansetron mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [37]
E-2007 DMJDYNQ Moderate Increased metabolism of Phenytoin caused by E-2007 mediated induction of CYP450 enzyme. Neuropathy [8C0Z] [37]
Bupropion DM5PCS7 Moderate Increased metabolism of Phenytoin caused by Bupropion mediated induction of CYP450 enzyme. Nicotine use disorder [6C4A] [40]
Entrectinib DMMPTLH Major Increased metabolism of Phenytoin caused by Entrectinib mediated induction of CYP450 enzyme. Non-small cell lung cancer [2C25] [178]
Levomethadyl Acetate DM06HG5 Major Increased metabolism of Phenytoin caused by Levomethadyl Acetate mediated induction of CYP450 enzyme. Opioid use disorder [6C43] [179]
S-297995 DM26IH8 Major Increased metabolism of Phenytoin caused by S-297995 mediated induction of CYP450 enzyme. Opioid use disorder [6C43] [180]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Phenytoin and Apraclonidine. Optic nerve disorder [9C40] [118]
Valdecoxib DMAY7H4 Moderate Increased metabolism of Phenytoin caused by Valdecoxib mediated induction of CYP450 enzyme. Osteoarthritis [FA00-FA05] [181]
Olaparib DM8QB1D Major Increased metabolism of Phenytoin caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [40]
Rucaparib DM9PVX8 Moderate Increased metabolism of Phenytoin caused by Rucaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [182]
MK-4827 DMLYGH4 Moderate Accelerated clearance of Phenytoin due to the transporter induction by MK-4827. Ovarian cancer [2C73] [183]
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Phenytoin and Dextropropoxyphene. Pain [MG30-MG3Z] [184]
Butorphanol DM5KYPJ Major Increased metabolism of Phenytoin caused by Butorphanol mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [40]
Aspirin DM672AH Minor Increased plasma concentration of Phenytoin and Aspirin due to competitive binding of plasma proteins. Pain [MG30-MG3Z] [185]
Ibuprofen DM8VCBE Minor Increased plasma concentration of Phenytoin and Ibuprofen due to competitive binding of plasma proteins. Pain [MG30-MG3Z] [186]
Prilocaine DMI7DZ2 Major Increased risk of methemoglobinemia by the combination of Phenytoin and Prilocaine. Pain [MG30-MG3Z] [60]
Codeine DMJX6ZG Moderate Increased metabolism of Phenytoin caused by Codeine mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [85]
Buprenorphine DMPRI8G Major Additive CNS depression effects by the combination of Phenytoin and Buprenorphine. Pain [MG30-MG3Z] [187]
Hydrocodone DMQ2JO5 Major Increased metabolism of Phenytoin caused by Hydrocodone mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [40]
Acetaminophen DMUIE76 Moderate Increased metabolism of Phenytoin caused by Acetaminophen mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [188]
Meperidine DMX4GND Moderate Increased metabolism of Phenytoin caused by Meperidine mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [189]
Oxycodone DMXLKHV Major Increased metabolism of Phenytoin caused by Oxycodone mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [40]
Istradefylline DM20VSK Major Increased metabolism of Phenytoin caused by Istradefylline mediated induction of CYP450 enzyme. Parkinsonism [8A00] [190]
Pimavanserin DMR7IVC Moderate Increased metabolism of Phenytoin caused by Pimavanserin mediated induction of CYP450 enzyme. Parkinsonism [8A00] [191]
Esomeprazole DM7BN0X Moderate Decreased metabolism of Phenytoin caused by Esomeprazole mediated inhibition of CYP450 enzyme. Peptic ulcer [DA61] [40]
Macimorelin DMQYJIR Moderate Increased metabolism of Phenytoin caused by Macimorelin mediated induction of CYP450 enzyme. Pituitary gland disorder [5A60-5A61] [192]
Lefamulin DME6G97 Major Accelerated clearance of Phenytoin due to the transporter induction by Lefamulin. Pneumonia [CA40] [193]
Prednisone DM2HG4X Moderate Increased metabolism of Phenytoin caused by Prednisone mediated induction of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [139]
Choline salicylate DM8P137 Minor Increased plasma concentration of Phenytoin and Choline salicylate due to competitive binding of plasma proteins. Postoperative inflammation [1A00-CA43] [185]
Betamethasone DMAHJEF Moderate Increased metabolism of Phenytoin caused by Betamethasone mediated induction of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [139]
Hydrocortisone DMGEMB7 Moderate Increased metabolism of Phenytoin caused by Hydrocortisone mediated induction of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [139]
Bromfenac DMKB79O Moderate Increased metabolism of Phenytoin caused by Bromfenac mediated induction of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [194]
Ergonovine DM0VEC1 Moderate Increased metabolism of Phenytoin caused by Ergonovine mediated induction of CYP450 enzyme. Postpartum haemorrhage [JA43] [40]
Lonafarnib DMGM2Z6 Major Increased metabolism of Phenytoin caused by Lonafarnib mediated induction of CYP450 enzyme. Premature ageing appearance [LD2B] [195]
Progesterone DMUY35B Moderate Increased metabolism of Phenytoin caused by Progesterone mediated induction of CYP450 enzyme. Preterm labour/delivery [JB00] [72]
ABIRATERONE DM8V75C Major Increased metabolism of Phenytoin caused by ABIRATERONE mediated induction of CYP450 enzyme. Prostate cancer [2C82] [196]
Enzalutamide DMGL19D Moderate Increased metabolism of Phenytoin caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [197]
Relugolix DMK7IWL Major Increased metabolism of Phenytoin caused by Relugolix mediated induction of CYP450 enzyme. Prostate cancer [2C82] [198]
Darolutamide DMV7YFT Major Increased metabolism of Phenytoin caused by Darolutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [199]
Silodosin DMJSBT6 Moderate Accelerated clearance of Phenytoin due to the transporter induction by Silodosin. Prostate hyperplasia [GA90] [40]
Ustekinumab DMHTYK3 Moderate Altered metabolism of Phenytoin due to Ustekinumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [37]
Apremilast DMTWS9E Major Increased metabolism of Phenytoin caused by Apremilast mediated induction of CYP450 enzyme. Psoriasis [EA90] [200]
Ixekizumab DMXW92T Moderate Altered metabolism of Phenytoin due to Ixekizumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [37]
Bosentan DMIOGBU Moderate Increased metabolism of Phenytoin caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [40]
Treprostinil DMTIQF3 Moderate Increased metabolism of Phenytoin caused by Treprostinil mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [60]
Riociguat DMXBLMP Moderate Increased metabolism of Phenytoin caused by Riociguat mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [201]
Axitinib DMGVH6N Major Increased metabolism of Phenytoin caused by Axitinib mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [202]
Temsirolimus DMS104F Major Increased metabolism of Phenytoin caused by Temsirolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [40]
Sorafenib DMS8IFC Moderate Increased metabolism of Phenytoin caused by Sorafenib mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [203]
Salsalate DM13P4C Minor Increased plasma concentration of Phenytoin and Salsalate due to competitive binding of plasma proteins. Rheumatoid arthritis [FA20] [185]
Upadacitinib DM32B5U Major Increased metabolism of Phenytoin caused by Upadacitinib mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [204]
Tocilizumab DM7J6OR Moderate Altered metabolism of Phenytoin due to Tocilizumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [37]
Canakinumab DM8HLO5 Moderate Altered metabolism of Phenytoin due to Canakinumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [37]
Tofacitinib DMBS370 Major Increased metabolism of Phenytoin caused by Tofacitinib mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [40]
Rilonacept DMGLUQS Moderate Altered metabolism of Phenytoin due to Rilonacept alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [37]
Golimumab DMHZV7X Moderate Altered metabolism of Phenytoin due to Golimumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [37]
Dexamethasone DMMWZET Moderate Increased metabolism of Phenytoin caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [139]
Nafcillin DMN9RPO Minor Increased plasma concentration of Phenytoin and Nafcillin due to competitive binding of plasma proteins. Rheumatoid arthritis [FA20] [62]
Sarilumab DMOGNXY Moderate Altered metabolism of Phenytoin due to Sarilumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [37]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Phenytoin and Leflunomide. Rheumatoid arthritis [FA20] [97]
Quetiapine DM1N62C Major Increased metabolism of Phenytoin caused by Quetiapine mediated induction of CYP450 enzyme. Schizophrenia [6A20] [40]
Aripiprazole DM3NUMH Moderate Increased metabolism of Phenytoin caused by Aripiprazole mediated induction of CYP450 enzyme. Schizophrenia [6A20] [205]
Haloperidol DM96SE0 Major Increased metabolism of Phenytoin caused by Haloperidol mediated induction of CYP450 enzyme. Schizophrenia [6A20] [60]
Salicyclic acid DM2F8XZ Minor Increased plasma concentration of Phenytoin and Salicyclic acid due to competitive binding of plasma proteins. Seborrhoeic dermatitis [EA81] [185]
Fentanyl DM8WAHT Major Increased metabolism of Phenytoin caused by Fentanyl mediated induction of CYP450 enzyme. Sensation disturbance [MB40] [40]
Avanafil DM75CXN Moderate Increased metabolism of Phenytoin caused by Avanafil mediated induction of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [206]
Tadalafil DMJZHT1 Moderate Increased metabolism of Phenytoin caused by Tadalafil mediated induction of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [37]
Voxelotor DMCS6M5 Major Increased metabolism of Phenytoin caused by Voxelotor mediated induction of CYP450 enzyme. Sickle-cell disorder [3A51] [207]
LDE225 DMM9F25 Major Increased metabolism of Phenytoin caused by LDE225 mediated induction of CYP450 enzyme. Skin cancer [2C30-2C37] [208]
Gefitinib DM15F0X Moderate Increased metabolism of Phenytoin caused by Gefitinib mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [149]
Larotrectinib DM26CQR Major Accelerated clearance of Phenytoin due to the transporter induction by Larotrectinib. Solid tumour/cancer [2A00-2F9Z] [40]
Methylprednisolone DM4BDON Moderate Increased metabolism of Phenytoin caused by Methylprednisolone mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [139]
Cyclophosphamide DM4O2Z7 Moderate Increased metabolism of Phenytoin caused by Cyclophosphamide mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [75]
Vinblastine DM5TVS3 Moderate Increased metabolism of Phenytoin caused by Vinblastine mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [164]
Docetaxel DMDI269 Moderate Increased metabolism of Phenytoin caused by Docetaxel mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [209]
Trabectedin DMG3Y89 Major Increased metabolism of Phenytoin caused by Trabectedin mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [37]
LEE011 DMMX75K Major Increased metabolism of Phenytoin caused by LEE011 mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [210]
Etoposide DMNH3PG Moderate Increased metabolism of Phenytoin caused by Etoposide mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [211]
Epirubicin DMPDW6T Moderate Increased risk of hepatotoxicity by the combination of Phenytoin and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [40]
Prednisolone DMQ8FR2 Moderate Increased metabolism of Phenytoin caused by Prednisolone mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [139]
Vandetanib DMRICNP Moderate Increased metabolism of Phenytoin caused by Vandetanib mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [212]
Taxol DMUOT9V Moderate Increased metabolism of Phenytoin caused by Taxol mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [213]
Vinorelbine DMVXFYE Moderate Accelerated clearance of Phenytoin due to the transporter induction by Vinorelbine. Solid tumour/cancer [2A00-2F9Z] [164]
Pitolisant DM8RFNJ Major Increased metabolism of Phenytoin caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [37]
Disulfiram DMCL2OK Moderate Decreased metabolism of Phenytoin caused by Disulfiram mediated inhibition of CYP450 enzyme. Substance abuse [6C40] [214]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Phenytoin and Naltrexone. Substance abuse [6C40] [215]
Warfarin DMJYCVW Moderate Increased metabolism of Phenytoin caused by Warfarin mediated induction of CYP450 enzyme. Supraventricular tachyarrhythmia [BC81] [86]
Pomalidomide DMTGBAX Moderate Increased metabolism of Phenytoin caused by Pomalidomide mediated induction of CYP450 enzyme. Systemic sclerosis [4A42] [216]
Fostamatinib DM6AUHV Major Increased metabolism of Phenytoin caused by Fostamatinib mediated induction of CYP450 enzyme. Thrombocytopenia [3B64] [217]
As-1670542 DMV05SW Major Increased metabolism of Phenytoin caused by As-1670542 mediated induction of CYP450 enzyme. Thrombocytopenia [3B64] [218]
Apixaban DM89JLN Major Accelerated clearance of Phenytoin due to the transporter induction by Apixaban. Thrombosis [DB61-GB90] [37]
Brilinta DMBR01X Major Increased metabolism of Phenytoin caused by Brilinta mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [219]
Dicumarol DMFQCB1 Moderate Increased metabolism of Phenytoin caused by Dicumarol mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [220]
Clopidogrel DMOL54H Minor Decreased metabolism of Phenytoin caused by Clopidogrel mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [221]
Cabozantinib DMIYDT4 Major Increased metabolism of Phenytoin caused by Cabozantinib mediated induction of CYP450 enzyme. Thyroid cancer [2D10] [222]
Pipecuronium DM5F84A Moderate Increased metabolism of Phenytoin caused by Pipecuronium mediated induction of CYP450 enzyme. Tonus and reflex abnormality [MB47] [91]
Doxacurium DMKE7L9 Moderate Increased metabolism of Phenytoin caused by Doxacurium mediated induction of CYP450 enzyme. Tonus and reflex abnormality [MB47] [91]
Cisatracurium DMUZPJ5 Moderate Increased metabolism of Phenytoin caused by Cisatracurium mediated induction of CYP450 enzyme. Tonus and reflex abnormality [MB47] [91]
Rocuronium DMY9BMK Moderate Increased metabolism of Phenytoin caused by Rocuronium mediated induction of CYP450 enzyme. Tonus and reflex abnormality [MB47] [91]
Sirolimus DMGW1ID Major Increased metabolism of Phenytoin caused by Sirolimus mediated induction of CYP450 enzyme. Transplant rejection [NE84] [40]
Mycophenolate mofetil DMPQAGE Minor Increased plasma concentration of Phenytoin and Mycophenolate mofetil due to competitive binding of plasma proteins. Transplant rejection [NE84] [95]
Tacrolimus DMZ7XNQ Major Increased metabolism of Phenytoin caused by Tacrolimus mediated induction of CYP450 enzyme. Transplant rejection [NE84] [40]
Canagliflozin DMFRM1I Moderate Increased metabolism of Phenytoin caused by Canagliflozin mediated induction of UGT. Type 2 diabetes mellitus [5A11] [40]
Linagliptin DMWFJTR Moderate Increased metabolism of Phenytoin caused by Linagliptin mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [223]
Trimethoprim DMM7CHK Moderate Decreased metabolism of Phenytoin caused by Trimethoprim mediated inhibition of CYP450 enzyme. Urinary tract infection [GC08] [224]
Elagolix DMB2C0E Moderate Increased metabolism of Phenytoin caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [225]
Triamcinolone DM98IXF Moderate Increased metabolism of Phenytoin caused by Triamcinolone mediated induction of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [139]
Betrixaban DM2C4RF Moderate Accelerated clearance of Phenytoin due to the transporter induction by Betrixaban. Venous thromboembolism [BD72] [226]
Disopyramide DM5SYZP Moderate Increased metabolism of Phenytoin caused by Disopyramide mediated induction of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [227]
Mexiletine DMCTE9R Moderate Increased metabolism of Phenytoin caused by Mexiletine mediated induction of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [228]
⏷ Show the Full List of 369 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Benzyl alcohol E00010 244 Antimicrobial preservative; Solvent
Butylparaben E00142 7184 Antimicrobial preservative
D&C red no. 28 E00491 6097185 Colorant
D&C red no. 30 E00456 3000709 Colorant
D&C red no. 33 E00261 19116 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
methylparaben E00149 7456 Antimicrobial preservative
Propyl 4-hydroxybenzoate E00141 7175 Antimicrobial preservative
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
Ammonia E00007 222 Alkalizing agent
Butyl alcohol E00011 263 Flavoring agent; Solvent
Edetate calcium disodium E00487 6093170 Complexing agent
FD&C red no. 3 E00629 Not Available Colorant
Ferrosoferric oxide E00231 14789 Colorant
Lactitol monohydrate E00459 3067270 Diluent; Flavoring agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium oxide E00232 14792 Anticaking agent; Diluent; Emulsifying agent; Glidant; Tonicity agent
Magnesium stearate E00208 11177 lubricant
Potassium hydroxide E00233 14797 Alkalizing agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium propionate E00445 2723816 Antimicrobial preservative
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Water E00035 962 Solvent
⏷ Show the Full List of 32 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Phenytoin 100 mg capsule 100 mg Extended Release Oral Capsule Oral
Phenytoin 200 mg capsule 200 mg Extended Release Oral Capsule Oral
Phenytoin 300 mg capsule 300 mg Extended Release Oral Capsule Oral
Phenytoin 100 mg capsule 100 mg Oral Capsule Oral
Phenytoin 30 mg capsule 30 mg Extended Release Oral Capsule Oral
Phenytoin 50 mg tablet 50 mg Chewable Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Phenytoin FDA Label
3 Gupta M, Tripp J: Phenytoin .
4 BDDCS applied to over 900 drugs
5 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7 Dilantin? FDA Label (injectable formulation)
8 Lachance S, Dhingra O, Bernstein J, Gagnon S, Savard C, Pelletier N, Boudreau N, Levesque A: Importance of measuring testosterone in enzyme-inhibited plasma for oral testosterone undecanoate androgen replacement therapy clinical trials. Future Sci OA. 2015 Nov 1;1(4):FSO55. doi: 10.4155/fso.15.55. eCollection 2015 Nov.
9 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
10 Bergen DC: Pharmacokinetics of phenytoin: reminders and discoveries. Epilepsy Curr. 2009 Jul-Aug;9(4):102-4. doi: 10.1111/j.1535-7511.2009.01307.x.
11 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
12 Genome-wide mapping for clinically relevant predictors of lamotrigine- and phenytoin-induced hypersensitivity reactions. Pharmacogenomics. 2012 Mar;13(4):399-405. doi: 10.2217/pgs.11.165.
13 Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics. 2010 Mar;11(3):349-56. doi: 10.2217/pgs.09.162.
14 Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68.
15 Upregulation of brain expression of P-glycoprotein in MRP2-deficient TR(-) rats resembles seizure-induced up-regulation of this drug efflux transporter in normal rats. Epilepsia. 2007 Apr;48(4):631-45.
16 Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. Neuropharmacology. 2010 Jun;58(7):1019-32.
17 The transport of antiepileptic drugs by P-glycoprotein. Adv Drug Deliv Rev. 2012 Jul;64(10):930-42.
18 Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1034-40.
19 Antiepileptic drug interactions - principles and clinical implications. Curr Neuropharmacol. 2010 Sep;8(3):254-67.
20 Comparison of basal glutathione S-transferase activities and of the influence of phenobarbital, butylated hydroxy-anisole or 5,5'-diphenylhydantoin on enzyme activity in male rodents. Comp Biochem Physiol C. 1987;88(1):91-3.
21 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
22 PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
23 Impaired degradation of matrix collagen in human gingival fibroblasts by the antiepileptic drug phenytoin. J Periodontol. 2005 Jun;76(6):941-50. doi: 10.1902/jop.2005.76.6.941.
24 Role of phenytoin in wound healing: microarray analysis of early transcriptional responses in human dermal fibroblasts. Biochem Biophys Res Commun. 2004 Feb 13;314(3):661-6. doi: 10.1016/j.bbrc.2003.12.146.
25 Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
26 Inhibition of human aromatase complex (CYP19) by antiepileptic drugs. Toxicol In Vitro. 2008 Feb;22(1):146-53.
27 Intestinal expression of cytochrome P450 enzymes and ABC transporters and carbamazepine and phenytoin disposition. Acta Neurol Scand. 2007 Apr;115(4):232-42. doi: 10.1111/j.1600-0404.2006.00761.x.
28 Backman JT, Olkkola KT, Ojala M, Laaksovirta H, Neuvonen PJ "Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin." Epilepsia 37 (1996): 253-7. [PMID: 8598183]
29 Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data." Eur J Clin Pharmacol 54 (1998): 177-83. [PMID: 9626925]
30 Kuranari M, Tatsukawa H, Seike M, et al. "Effect of phenytoin on phenobarbital pharmacokinetics in a patient with epilepsy." Ann Pharmacother 29 (1995): 83-4. [PMID: 7711354]
31 Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
32 Browne TR, Feldman RG, Buchanan RA, et al. "Methsuximide for complex partial seizures: efficacy, toxicity, clinical pharmacology, and drug interactions." Neurology 33 (1983): 414-8. [PMID: 6403891]
33 Bourgeois BF "Pharmacologic interactions between valproate and other drugs." Am J Med 84 (1988): 29-33. [PMID: 3146222]
34 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
35 Product Information. Gabitril (tiagabine). Abbott Pharmaceutical, Abbott Park, IL.
36 Cazali N, Tran A, Treluyer JM, et al. "Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human." Br J Clin Pharmacol 56 (2003): 526-36. [PMID: 14651727]
37 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
38 Gratz ES, Theodore WH, Newmark ME, Kupferberg HJ, Porter RJ, Qu Z "Effect of carbamazepine on phenytoin clearance in patients with complex partial seizures." Neurology 32 (1982): a223.
39 Bialer M, Soares-da-Silva P "Pharmacokinetics and drug interactions of eslicarbazepine acetate." Epilepsia 53 (2012): 935-46. [PMID: 22612290]
40 Cerner Multum, Inc. "Australian Product Information.".
41 Bernard A, Kermarrec G, Parize P, et.al "Dramatic reduction of clindamycin serum concentration in staphylococcal osteoarticular infection patients treated with the oral clindamycin-rifampicin combination." J Infect 71 (2015): 200-6. [PMID: 25936632]
42 McCarthy DM "Sucralfate." N Engl J Med 325 (1991): 1017-25. [PMID: 1886624]
43 Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14. [PMID: 12919179]
44 Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
45 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
46 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
47 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
48 Product Information. Lysodren (mitotane). Bristol-Myers Squibb, Princeton, NJ.
49 Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
50 Blyden GT, Scavone JM, Greenblatt DJ "Metronidazole impairs clearance of phenytoin but not of alprazolam or lorazepam." J Clin Pharmacol 28 (1988): 240-5. [PMID: 3360972]
51 Product Information. Mycobutin (rifabutin). Pharmacia and Upjohn, Kalamazoo, MI.
52 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
53 Kivisto KT, Lamberg TS, Neuvonen PJ "Interactions of buspirone with itraconazole and rifampicin: Effects on the pharmacokinetics of the active 1-(2-pyrimidinyl)-piperazine metabolite of buspirone." Pharmacol Toxicol 84 (1999): 94-7. [PMID: 10068153]
54 Murphy A, Wilbur K "Phenytoin-diazepam interaction." Ann Pharmacother 37 (2003): 659-63. [PMID: 12708941]
55 Alffenaar JW, van der Elst KC, Uges DR, Kosterink JG, Daenen SM "Phenytoin-induced reduction of voriconazole serum concentration is not compensated by doubling the dosage." Br J Clin Pharmacol 68 (2009): 462-3. [PMID: 19740405]
56 Product Information. Singulair (montelukast). Merck & Co, Inc, West Point, PA.
57 Crowley JJ, Cusack BJ, Jue SG, et al "Cigarette smoking and theophylline metabolism: effects of phenytoin." Clin Pharmacol Ther 42 (1987): 334-40. [PMID: 3621789]
58 Nassr N, Huennemeyer A, Herzog R, et al. "Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects." Br J Clin Pharmacol 68 (2009): 580-7. [PMID: 19843061]
59 Garrettson LK, Perel JM, Dayton PG "Methylphenidate interaction with both anticonvulsants and ethyl biscoumacetate." JAMA 207 (1969): 1053-6. [PMID: 5818377]
60 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
61 Bachmann K, Schwartz JI, Forney RB Jr, Jauregui L "Single dose phenytoin clearance during erythromycin treatment." Res Commun Chem Pathol Pharmacol 46 (1984): 207-17. [PMID: 6515115]
62 Dasgupta A, Dennen DA, Dean R, McLawhon RW "Displacement of phenytoin from serum protein carriers by antibiotics: studies with ceftriaxone, nafcillin, and sulfamethoxazole." Clin Chem 37 (1991): 98-100. [PMID: 1988217]
63 Product Information. Potiga (ezogabine). GlaxoSmithKline, Research Triangle Park, NC.
64 American Epilepsy Society "FDA Safety Warning on the Cardiac Effects of Lamotrigine: An Advisory from the Ad Hoc ILAE/AES Task Force. [PMID: 33641454]
65 Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
66 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
67 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
68 Product Information. Alinia (nitazoxanide). Romark Laboratories L.C., Tampa, FL.
69 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
70 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
71 Product Information. Aromasin (exemestane) Pharmacia & Upjohn, Kalamazoo, MI.
72 Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985): 26-35. [PMID: 2859674]
73 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
74 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
75 de Jonge ME, Huitema AD, van Dam SM, Beijnen JH, Rodenhuis S "Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin." Cancer Chemother Pharmacol 55 (2005): 507-10. [PMID: 15685452]
76 Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8. [PMID: 9037249]
77 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
78 Berthou F, Dreano Y, Belloc C, Kangas L, Gautier JC, Beaune P "Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes." Biochem Pharmacol 47 (1994): 1883-95. [PMID: 8204106]
79 Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
80 Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61. [PMID: 7009137]
81 Bullman J, Nicholls A, Van Landingham K, et al. "Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers." Epilepsia 52 (2011): 1351-8. [PMID: 21635243]
82 Bruderer S, Aanismaa P, Homery MC, et al. "Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist." AAPS J 14 (2012): 68-78. [PMID: 22189899]
83 Product Information. Hectorol (doxercalciferol). Genzyme Corporation, Cambridge, MA.
84 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
85 Caraco Y, Sheller J, Wood AJ "Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects." J Pharmacol Exp Ther 281 (1997): 330-6. [PMID: 9103514]
86 Hansen JM, Siersboek-Nielsen K, Skovsted L "Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man." Clin Pharmacol Ther 12 (1971): 539-43. [PMID: 5567804]
87 Product Information. Stivarga (regorafenib). Bayer Pharmaceutical Inc, West Haven, CT.
88 Crews KR, Stewart CF, Jones-Wallace D, et al "Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy." Clin Cancer Res 8 (2002): 2202-9. [PMID: 12114421]
89 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
90 Back DJ, Grimmer SF, Orme ML, Proudlove D, Mann RD, Breckenridge AM "Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics." Br J Clin Pharmacol 25 (1988): 527-32. [PMID: 3408633]
91 Liberman BA, Norman P, Hardy BG "Pancuronium-phenytoin interaction: a case of decreased duration of neuromuscular blockade." Int J Clin Pharmacol Ther Toxicol 26 (1988): 371-4. [PMID: 3220609]
92 Kharasch ED, Thummel KE "Human alfentanil metabolism by cytochrome P450 3A3/4. An explanation for the interindividual variability in alfentanil clearance?" Anesth Analg 76 (1993): 1033-9. [PMID: 8484504]
93 Bahls FH, Ozuna J, Ritchie DE "Interactions between calcium channel blockers and the anticonvulsants carbamazepine and phenytoin." Neurology 41 (1991): 740-2. [PMID: 2027492]
94 Altice FL, Friedland GH, Cooney EL "Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone." AIDS 13 (1999): 957-62. [PMID: 10371177]
95 Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
96 Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
97 Canadian Pharmacists Association.
98 Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
99 Jalil P "Toxic reaction following the combined administration of fluoxetine and phenytoin: two case reports." J Neurol Neurosurg Psychiatry 55 (1992): 412-3. [PMID: 1602320]
100 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
101 Belcastro V, Costa C, Striano P "Levetiracetam-associated hyponatremia." Seizure 17 (2008): 389-90. [PMID: 18584781]
102 Product Information. Brintellix (vortioxetine). Takeda Pharmaceuticals America, Lincolnshire, IL.
103 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
104 Product Information. Remeron (mirtazapine). Organon, West Orange, NJ.
105 Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
106 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
107 Bittencourt PR, Gracia CM, Martins R, et al "Phenytoin and carbamazepine decrease oral bioavailability of praziquantel." Neurology 42 (1992): 492-6. [PMID: 1549207]
108 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
109 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
110 Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
111 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
112 Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
113 Product Information. Cancidas (caspofungin) Merck & Co, Inc, West Point, PA.
114 Rolan PE, Somogyi AA, Drew MJ, et al "Phenytoin intoxication during treatment with parenteral miconazole." Br Med J (Clin Res Ed) 287 (1983): 1760. [PMID: 6416579]
115 Andersson T "Omeprazole drug interaction studies." Clin Pharmacokinet 21 (1991): 195-212. [PMID: 1764870]
116 Algozzine GJ, Stewart RB, Springer PK "Decreased clearance of phenytoin with cimetidine." Ann Intern Med 95 (1981): 244-5. [PMID: 7258891]
117 Product Information. Qinlock (ripretinib). Deciphera Pharmaceuticals, Waltham, MA.
118 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
119 Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.
120 Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
121 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
122 Abajo FJ "Phenytoin interaction with rifampicin." Br Med J 297 (1988): 1048. [PMID: 3142625]
123 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
124 Product Information. Pretomanid (pretomanid). The Global Alliance for TB Drug Development, New York, NY.
125 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
126 Product Information. Cerebyx (fosphenytoin). Parke-Davis, Morris Plains, NJ.
127 Barry M, Gibbons S, Back D, Mulcahy F "Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations." Clin Pharmacokinet 32 (1997): 194-209. [PMID: 9084959]
128 Acosta EP, Henry K, Baken L, Page LM, Fletcher CV "Indinavir concentrations and antiviral effect." Pharmacotherapy 19 (1999): 708-12. [PMID: 10391416]
129 Anderson GD "Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs." Neurology 63(10 Suppl 4) (2004): S3-8. [PMID: 15557548]
130 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
131 Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ.
132 Cerner Multum, Inc. "Canadian Product Information.".
133 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
134 Product Information. Atromid-S (clofibrate). Wyeth-Ayerst Laboratories, Philadelphia, PA.
135 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
136 Fischer TL, Pieper JA, Graff DW, et al. "Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers." Clin Pharmacol Ther 72 (2002): 238-46. [PMID: 12235444]
137 Ahmad S "Nifedipine-phenytoin interaction." J Am Coll Cardiol 3 (1984): 1582. [PMID: 6425385]
138 Petro DJ, Vannucci RC, Kulin HE "Diazoxide-diphenylhydantoin interaction." J Pediatr 89 (1976): 331-2. [PMID: 940040]
139 Frey BM, Frey FJ "Phenytoin modulates the pharmacokinetics of prednisolone and the pharmacodynamics of prednisolone as assessed by the inhibition of the mixed lymphocyte reaction in humans." Eur J Clin Invest 14 (1984): 1-6. [PMID: 6230241]
140 Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
141 Product Information. Xerava (eravacycline). Tetraphase Pharmaceuticals, Inc, Watertown, MA.
142 Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
143 Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
144 Product Information. Lunesta (eszopiclone). Sepracor Inc, Marlborough, MA.
145 Product Information. Sonata (zaleplon) Wyeth-Ayerst Laboratories, Philadelphia, PA.
146 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
147 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
148 Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
149 Li J, Zhao M, He P, Hidalgo M, Baker SD "Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes." Clin Cancer Res 13 (2007): 3731-7. [PMID: 17575239]
150 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
151 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
152 Product Information. Gilotrif (afatinib). Boehringer Ingelheim, Ridgefield, CT.
153 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
154 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
155 Product Information. Artesunate (artesunate). Amivas, Frederick, MD.
156 Fabre C, Criddle J, Nolder D, Klein JL "Recrudescence of imported falciparum malaria after quinine therapy: potential drug interaction with phenytoin." Trans R Soc Trop Med Hyg 99 (2005): 871-3. [PMID: 16099004]
157 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
158 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
159 Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
160 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
161 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
162 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
163 Product Information. Blincyto (blinatumomab). Amgen USA, Thousand Oaks, CA.
164 Bollini P, Riva R, Albani F, Ida et al "Decreased phenytoin level during antineoplastic therapy: a case report." Epilepsia 24 (1983): 75-8. [PMID: 6822234]
165 Baker DK, Relling MV, Pui CH, Christensen ML, Evans WE, Rodman JH "Increased teniposide clearance with concomitant anticonvulsant therapy." J Clin Oncol 10 (1992): 311-5. [PMID: 1732431]
166 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
167 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
168 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
169 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
170 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
171 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
172 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
173 Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
174 Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
175 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
176 Bolton AE, Peng B, Hubert M, et al. "Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects." Cancer Chemother Pharmacol 53 (2004): 102-6. [PMID: 14605865]
177 Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
178 Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
179 Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John's Wort." Am J Med 112 (2002): 507-8. [PMID: 11959071]
180 Product Information. Symproic (naldemedine). Shionogi USA Inc, Florham Park, NJ.
181 Product Information. Bextra (valdecoxib). Pharmacia Corporation, Peapack, NJ.
182 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
183 Product Information. Zejula (niraparib). Tesaro Inc., Waltham, MA.
184 Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
185 Fraser DG, Ludden TM, Evens RP, Sutherland EW "Displacement of phenytoin from plasma binding sites by salicylate." Clin Pharmacol Ther 27 (1980): 165-9. [PMID: 7353334]
186 Bachmann KA, Schwartz JI, Forney RB Jr, et al "Inability of ibuprofen to alter single dose phenytoin disposition." Br J Clin Pharmacol 21 (1986): 165-9. [PMID: 3954932]
187 Center for Substance Abuse Treatment.?Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2004. [PMID: 22514846]
188 Bivins BA, Rapp RP, Griffen WO Jr, Blouin R, Bustrack J "Dopamine-phenytoin interaction. A cause of hypotension in the critically ill." Arch Surg 113 (1978): 245-9. [PMID: 637689]
189 Pond SM, Kretschzmar KM "Effect of phenytoin on meperidine clearance and normeperidine formation." Clin Pharmacol Ther 30 (1981): 680-6. [PMID: 7297025]
190 Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
191 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
192 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
193 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
194 Gumbhirshah K, Cevallos WH, Decleene SA, Korthbradley JM "Evaluation of pharmacokinetic interaction between bromfenac and phenytoin in healthy males." J Clin Pharmacol 37 (1997): 160-8. [PMID: 9055143]
195 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
196 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
197 Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
198 Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
199 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
200 Product Information. Otezla (apremilast). Celgene Corporation, Summit, NJ.
201 Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.
202 Pithavala YK, Tortorici M, Toh M, et al "Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers." Cancer Chemother Pharmacol 65 (2010): 563-70. [PMID: 19603168]
203 Product Information. Nexavar (sorafenib). Bayer Pharmaceutical Inc, West Haven, CT.
204 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
205 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
206 Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
207 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
208 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
209 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
210 Product Information. Kisqali (ribociclib). Novartis Pharmaceuticals, East Hanover, NJ.
211 Rodman JH, Murry DJ, Madden T, Santana VM "Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation." J Clin Oncol 12 (1994): 2390-7. [PMID: 7964955]
212 Martin P, Oliver S, Robertson J, Kennedy SJ, Read J, Duvauchelle T "Pharmacokinetic drug interactions with vandetanib during cadministration with rifampicin or itraconazole." Drugs R D 11 (2011): 37-51. [PMID: 21410294]
213 Jamis-Dow CA, Klecker RW, Katki AG, Collins JM "Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993.
214 Brown CG, Kaminsky MJ, Feroli ER, Gurley HT "Delirium with phenytoin and disulfiram administration." Ann Emerg Med 12 (1983): 310-3. [PMID: 6625283]
215 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
216 Product Information. Pomalyst (pomalidomide). QLT Phototherapeutics Inc, Vancouver, AZ.
217 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
218 Nomo, Zamora, Schuck, et al. "Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting." PubMed 84 (2018): 1. [PMID: 29341245]
219 Product Information. Brilinta (ticagrelor). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
220 Koch-Weser J, Sellers EM "Drug interactions with coumarin anticoagulants (first of two parts)." N Engl J Med 285 (1971): 487-98. [PMID: 4397794]
221 Product Information. Plavix (clopidogrel). Bristol-Myers Squibb, Princeton, NJ.
222 Product Information. Cabometyx (cabozantinib). Exelixis Inc, S San Francisco, CA.
223 Product Information. Tradjenta (linagliptin). Boehringer Ingelheim, Ridgefield, CT.
224 Antoniou T, Gomes T, Mamdani MM, Juurlink DN "Trimethoprim/sulfamethoxazole-induced phenytoin toxicity in the elderly: a population-based study." Br J Clin Pharmacol 71 (2011): 544-9. [PMID: 21395647]
225 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.
226 Gelosa P, Castiglioni L, Tenconi M, et.al "Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs)" Pharmacol Res 135 (2018): 60-79. [PMID: 30040996]
227 Aitio ML, Mansury L, Tala E, et al "The effect of enzyme induction on the metabolism of disopyramide in man." Br J Clin Pharmacol 11 (1981): 279-85. [PMID: 7213529]
228 Begg EJ, Chinwah PM, Webb C, Day RO, Wade DN "Enhanced metabolism of mexiletine after phenytoin administration." Br J Clin Pharmacol 14 (1982): 219-23. [PMID: 7104173]